Vivus's obesity drug Qnexa exceeds expectations in Phase III
11 September 2009
Katie McQue
Please Login to read the full article.
11 September 2009
Katie McQue
katie.mcque@informa.com
Vivus's obesity drug Qnexa (topiramate and phentermine) has met the primary endpoint of two Phase III studies, EQUIP and CONQUER, demonstrating a significant weight loss compared with placebo.
The Californian firms' share price rose by 71% to close at $11.80 on Nasdaq on September 9th.
The...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Vivus narrows indication for Qnexa obesity drug to FDA to enable Q2 2012 approval
- Lancet reports new positive cardio, metabolic data for Vivus' Qnexa
- US FDA targets 17 April 2012 for Qnexa decision; Vivus shares rise
- Vivus soars on FDA deal marking path forward for obesity drug
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
09 February 2012
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
